• 23 March 2018

    Study finds 62% of drug safety experts prefer AI

    A new study conducted by Oracle Health Sciences and Informa Engage/Pharma Intelligence has showed that 62% of drug safety experts prefer using artificial intelligence (AI) for adverse event (AE) processing.

  • 22 March 2018

    UK patients given early access to Akcea’s FCS drug

    Akcea Therapeutics has announced that volanesorsen, a drug for treating familial chylomicronaemia syndrome (FCS), has been granted a positive scientific opinion through the Early Access to Medicines Scheme (EAMS) by...

  • 22 March 2018

    Helsinn to purchase skin cancer drug Valchlor from Actelion

    Swiss pharmaceutical group Helsinn has signed a definitive agreement with Actelion Pharmaceuticals to obtain worldwide rights to Valchlor/Ledaga (mechlorethamine/chlormethine) for the treatment of mycosis fungoides‐type cutaneous T‐cell lymphoma (MF-CTCL), a...